

*Southwest Import District Office:* 4040 North Central Expressway, suite 300, Dallas, TX 75204.

PACIFIC REGION

*Regional Field Office:* 1301 Clay St., suite 1180–N, Oakland, CA 94512–5217.

*San Francisco District Office:* 1431 Harbor Bay Pkwy., Alameda, CA 94502–7070.

*Los Angeles District Office:* 19701 Fairchild, Irvine, CA 92612.

*Seattle District Office:* 22201 23rd Dr. SE., Bothell, WA 98021–4421.

*Pacific Regional Laboratory, SW:* 19701 Fairchild, Irvine, CA 92612.

*Pacific Regional Laboratory, NW:* 22201 23rd Dr. SE., Bothell, WA 98021–4421.

**PART 7—ENFORCEMENT POLICY**

**Subpart A—General Provisions**

Sec.

7.1 Scope.

7.3 Definitions.

7.12 Guaranty.

7.13 Suggested forms of guaranty.

**Subpart B [Reserved]**

**Subpart C—Recalls (Including Product Corrections)—Guidance on Policy, Procedures, and Industry Responsibilities**

7.40 Recall policy.

7.41 Health hazard evaluation and recall classification.

7.42 Recall strategy.

7.45 Food and Drug Administration-requested recall.

7.46 Firm-initiated recall.

7.49 Recall communications.

7.50 Public notification of recall.

7.53 Recall status reports.

7.55 Termination of a recall.

7.59 General industry guidance.

**Subpart D [Reserved]**

**Subpart E—Criminal Violations**

7.84 Opportunity for presentation of views before report of criminal violation.

7.85 Conduct of a presentation of views before report of criminal violation.

7.87 Records related to opportunities for presentation of views conducted before report of criminal violation.

AUTHORITY: 21 U.S.C. 321–393; 42 U.S.C. 241, 262, 263b–263n, 264.

SOURCE: 42 FR 15567, Mar. 22, 1977, unless otherwise noted.

**Subpart A—General Provisions**

**§ 7.1 Scope.**

This part governs the practices and procedures applicable to regulatory enforcement actions initiated by the Food and Drug Administration pursuant to the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 301 *et seq.*) and other laws that it administers. This part also provides guidance for manufacturers and distributors to follow with respect to their voluntary removal or correction of marketed violative products. This part is promulgated to clarify and explain the regulatory practices and procedures of the Food and Drug Administration, enhance public understanding, improve consumer protection, and assure uniform and consistent application of practices and procedures throughout the agency.

[43 FR 26218, June 16, 1978, as amended at 65 FR 56476, Sept. 19, 2000]

**§ 7.3 Definitions.**

(a) *Agency* means the Food and Drug Administration.

(b) *Citation* or *cite* means a document and any attachments thereto that provide notice to a person against whom criminal prosecution is contemplated of the opportunity to present views to the agency regarding an alleged violation.

(c) *Respondent* means a person named in a notice who presents views concerning an alleged violation either in person, by designated representative, or in writing.

(d) *Responsible individual* includes those in positions of power or authority to detect, prevent, or correct violations of the Federal Food, Drug, and Cosmetic Act.

(e) [Reserved]

(f) *Product* means an article subject to the jurisdiction of the Food and Drug Administration, including any food, drug, and device intended for human or animal use, any cosmetic and biologic intended for human use, and any item subject to a quarantine regulation under part 1240 of this chapter. *Product* does not include an electronic product that emits radiation and is subject to parts 1003 and 1004 of this chapter.